CPRX
HealthcareCatalyst Pharmaceuticals, Inc.
$22.80
$-0.35 (-1.51%)
Jan 5, 2026
Price History (1Y)
Analysis
Catalyst Pharmaceuticals, Inc. operates in the healthcare sector, specifically within the biotechnology industry. The company has a significant scale, with a market capitalization of $2.80 billion and revenue of $578.20 million (TTM). Additionally, Catalyst Pharmaceuticals employs 181 individuals. The company's financial health is marked by high profitability margins, including a gross margin of 83.1%, operating margin of 44.7%, and profit margin of 37.6%. Catalyst Pharmaceuticals also exhibits strong returns on equity at 27.5% and return on assets at 17.7%. The balance sheet indicates a manageable debt level of $2.89 million, accompanied by substantial cash reserves of $689.89 million. Catalyst Pharmaceuticals' valuation context is characterized by a price-to-earnings ratio (TTM) of 13.33 and forward P/E of 8.83. The company has demonstrated revenue growth of 15.3% year-over-year and earnings growth of 20.0%. Dividend information is not available, resulting in a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Visit website →Key Statistics
- Market Cap
- $2.80B
- P/E Ratio
- 13.33
- 52-Week High
- $26.58
- 52-Week Low
- $19.05
- Avg Volume
- 1.27M
- Beta
- 0.72
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 181